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Previewsevents that underlie these functional
changes before we can truly discern
what is primary and what is secondary.
The ultimate driving force of age-related
deterioration is the accumulation of de-
fects in the macromolecules and organ-
elles that make up the relevant cells.
Which types of faults contribute most to
functional declines of the cells (and there-
after the tissues) and how the kinetics of
such declines plays out across the life
course are chapters yet to be written.304 Cell Metabolism 18, September 3, 2013 ªREFERENCES
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Leptin mimics many of the antidiabetic actions of insulin in insulin-deficient diabetes, but the mechanism is
controversial. Fujikawa et al. (2013) reveal that leptin receptors in g-aminobutyric acid (GABA)-ergic and
pro-opiomelanocortin (POMC) neurons in the central nervous system are sufficient to mediate the lifesaving
and antidiabetic actions of leptin in insulin-deficient mice.The discovery of insulin in 1921–1922 and
its profound, lifesaving effect on people
with type 1 diabetes (T1DM) was one of
the miracles of modern medicine. Normal
glucose control without insulin seemed
impossible. Yet, recent studies demon-
strate that the adipocyte-secreted,
anorexigenic hormone, leptin, also has
potent antidiabetic actions in insulin-defi-
cient diabetes. In this issue, Fujikawa
et al. elucidate the underlying mecha-
nisms by identifying specific neuronal
subtypes that can mediate the glucose-
lowering effects of leptin in the absence
of insulin (Fujikawa et al., 2013).
Although insulin therapy is effective for
T1DM, diabetic complications including
retinopathy, nephropathy, cardiovascular
disease, and lower hindlimb amputation
are still major problems. Insulin therapy
lacks the precision necessary to mimic
the finely tuned dynamics of insulin secre-
tion from pancreatic b cells. Intensive
insulin treatment reduces the incidenceand progression of diabetic complica-
tions but increases the frequency of
severe hypoglycemia and may contribute
to increased adiposity, hepatic steatosis,
and adverse plasma lipoprotein profiles
in T1DM. Leptin could be a potential
adjunctive therapy for T1DM because of
its beneficial effects on glucose meta-
bolism and its antisteatotic and appetite-
suppressive effects (Wang et al., 2010;
Morton and Schwartz, 2011). Leptin
increases glucose utilization in peripheral
tissues, suppresses hepatic glucose pro-
duction, and reverses hyperglucagone-
mia in insulin-deficient rodents (German
et al., 2011; Wang et al., 2010) (Figure 1).
These effects are independent of leptin’s
anorexic effect and appear to be medi-
ated through the hypothalamus, although
the neuronal circuits are unknown.
Fujikawa et al. used two complemen-
tary models of insulin-deficient diabetes
induced by (1) the pancreatic b cell toxin
streptozotocin or (2) diphtheria toxintreatment in mice expressing the diph-
theria-toxin receptor driven by a rat insulin
promoter (RIP), which ablated nearly all
pancreatic b cells. To determine which
neuronal population(s) mediate the
effects of intracerebroventricular (i.c.v.)
leptin—leptin administered directly into
the brain ventricles—in insulin-deficient
mice, the authors deleted or re-expressed
the leptin receptor (LEPR) in a neuron
type-specific manner.
LEPR ablation selectively in POMC
neurons marginally blunted the hypergly-
cemia-lowering action of i.c.v. leptin in
insulin-deficient mice, and LEPR ablation
in steroidogenic factor 1 (SF1) neurons
(enriched in the ventromedial hypothala-
mus, VMH) had no effect. Furthermore,
LEPR re-expression in POMC neurons
alone in insulin-deficient mice lacking
LEPR in all other tissues failed to improve
hyperglycemia or survival in response to
i.c.v. leptin. In contrast, LEPR re-expres-
sion selectively in GABAergic neurons
Figure 1. Metabolic Effects of Insulin Deficiency and CNS Leptin in Type 1 Diabetes
(A) Alterations of glucose metabolism in T1DM. Autoimmune destruction of pancreatic b cells markedly
reduces insulin secretion, which increases glucagon secretion from pancreatic a cells. Hyperglucagone-
mia drives HGP resulting in hyperglycemia. Insulin deficiency reduces glucose utilization in peripheral tis-
sues such as BAT, white adipose tissue (WAT), and skeletal muscle, further contributing to hyperglycemia.
Insulin also regulates peripheral metabolism via the CNS, including inhibition of HGP and lipid metabolism
in WAT. Whether impairment of these central effects of insulin contributes to the metabolic abnormalities
in T1DM is unknown.
(B) Antidiabetic actions of leptin. Leptin is released mainly from white adipose tissue and acts through
LEPR onGABAergic as well as POMC neurons, to induce antidiabetic actions in the insulin-deficient state.
Leptin inhibits the activity of AgRP/NPY/GABA neurons, while it activates that of POMC neurons in the
ARC. The second-order neurons for leptin’s antidiabetic actions may be located in the paraventricular
hypothalamus (PVH), lateral hypothalamus (LH), VMH, or brainstem. LEPR in GABAergic neurons in other
hypothalamic regions such as the dorsomedial hypothalamus (DMH) or LH may also mediate leptin’s
actions on glycemia. Through its effects on GABAergic and POMC neurons, leptin suppresses HGP
and increases glucose utilization in peripheral tissues such as BAT and skeletal muscle. Suppression of
the hyperglucagonemia that is characteristic of insulin deficiency appears to be critical for the suppression
of HGPby leptin, whereas themechanism for the leptin-induced increase in glucose utilization is unknown.
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mice treated with i.c.v. leptin, partially
improved hyperglycemia, and fully
reversed hyperglucagonemia. LEPR re-
expression in both GABAergic and
POMC neurons had additive metabolic
effects and was sufficient to mediate the
lifesaving and antidiabetic effects of
leptin in insulin-deficient mice. The major
input was from GABAergic neurons.
Fujikawa et al.’s paper raises important
questions. First, which GABAergic neu-
rons mediate the antidiabetic effects of
leptin, and what are the target neurons?
GABAergic neurons expressing LEPRs
are present in the arcuate, dorsomedial
hypothalamus, and lateral hypothalamus.
Although leptin injection into VMH can
normalize diabetic hyperglycemia, LEPR
in SF1-expressing neurons is not neces-
sary for these effects (Meek et al., 2013,
Fujikawa et al., 2013). Leptin may act on
presynaptic GABAergic neurons pro-
jecting to the VMH or other regions. In
the arcuate, neuropeptide Y (NPY) and
agouti-related peptide (AgRP)-expressing
neurons corelease GABA, which potently
inhibits POMC neuronal activity. Leptin
suppresses the neuronal activity of NPY/
AgRP/GABAergic neurons, thereby acti-
vating POMC neurons (Morton and
Schwartz, 2011). Loss of GABAergic
signaling in a subset of arcuate AgRP/
NPY/GABAergic neurons that project
to the parabrachial nucleus leads to
starvation (Wu et al., 2009). Furthermore,
mice lacking GABA release in arcuate
RIP-expressing neurons have decreased
energy expenditure and become obese
via a circuit involving paraventricular
hypothalamic neurons (Kong et al.,
2012), underscoring the importance of
hypothalamic GABAergic neurons in
energy balance.
Second, what are the mechanism(s) for
leptin’s actions in peripheral tissues
(Figure 1), and is suppression of hyper-
glucagonemia critical? Glucagon appears
to be essential for development of hyper-
glycemia in insulin-deficient mice (Wang
et al., 2010). But the antidiabetic actions
of i.c.v. leptin are partial in diabetic
mice in which LEPR is re-expressed
in GABAergic neurons alone, while hyper-
glucagonemia is fully reversed. Thus, sup-
pression of hyperglucagonemia is not suf-
ficient for the full antidiabetic actions of
leptin. Furthermore, suppression of hy-
perglucagonemia does not explain theeptember 3, 2013 ª2013 Elsevier Inc. 305
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eral tissues. b-adrenergic receptors
mediate leptin-stimulated glucose uptake
in brown fat and muscle in lean, nondia-
betic rodents (Minokoshi et al., 1999).
But Fujikawa et al. showed that the antidi-
abetic actions of i.c.v. leptin were intact in
b1,b2,b3-adrenergic receptor-knockout
mice, indicating that different pathways
are engaged by hypothalamic neurons to
regulate glucose homeostasis in the pres-
ence and absence of insulin. Insulin-like
growth factor binding protein 2 is induced
in liver by leptin (Hedbacker et al., 2010),
and overexpression improves hypergly-
cemia in insulin-deficient mice. Whether
it mediates the antidiabetic effects of
i.c.v. leptin is unknown.
Third, how do the CNS effects of leptin
on glucose homeostasis integrate with
the peripheral and CNS effects of insulin?
Insulin inhibits hepatic glucose produc-
tion both directly and through the hypo-
thalamus (Figure 1) (Pocai et al., 2005).
The relative importance of these CNS
effects of insulin in normal physiology
and whether impairment of these effects
contributes to metabolic abnormalities in
T1DM is unknown. Furthermore, whether
CNS insulin acts through the same
GABAergic neurons as leptin is unknown.
The most fundamental question is
whether leptin therapy will be effective in
T1DM people. Independent of leptin’s
insulin-mimicking effects, its potential
appetite-suppressing effects could be
beneficial for glucose control in T1DM.
T1DM rodents are leptin deficient due to306 Cell Metabolism 18, September 3, 2013 ªreduced fat mass resulting from uncon-
trolled diabetes, while T1DM people who
are controlled with insulin therapy have
normal or increased fat mass. Thus,
leptin supplementation in leptin-sufficient
T1DM humans may not have the same
glycemic effects as leptin replacement in
leptin-deficient T1DM mice. Furthermore,
potential adverse effects of leptin such
as hypertension and proinflammatory
and procoagulatory effects may occur
when leptin levels are raised above
normal in T1DM humans. If used in com-
bination with insulin, leptin’s effect to
potently suppress glucagonmay increase
the risk for severe hypoglycemia in T1DM
people. Increased GABAergic output in
VMH contributes to impaired counterre-
gulatory responses to hypoglycemia in
diabetes.
Collectively, recent studies provide
convincing evidence that leptin has bene-
ficial effects on glucose homeostasis
in insulin-deficient (and leptin-deficient)
mice via the CNS. Fujikawa et al. found
that the vast majority of leptin’s antidia-
betic effects may be mediated by CNS
GABAergic neurons. While further studies
are needed to determine the full neuronal
circuitry, these findings extend our
understanding of CNS control of glucose
metabolism. Clinical studies are needed
to determine whether leptin or molecules
targeting the GABAergic pathways medi-
ating leptin’s glucose-lowering effects
could be effective and safe adjunctive
therapies for T1DM and whether, by
lowering the insulin dose, these could2013 Elsevier Inc.diminish some adverse effects of inten-
sive insulin therapy without increasing
the risk of hypoglycemia.REFERENCES
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